Welcome to our dedicated page for ZIMMER BIOMET HOLDINGS SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ZIMMER BIOMET HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ZIMMER BIOMET HOLDINGS's regulatory disclosures and financial reporting.
ZIMMER BIOMET HOLDINGS, INC. executive Chad F. Phipps exercised restricted stock units into common stock and used a portion of the resulting shares to cover taxes. On March 6, 2026, RSUs representing 6,786 shares of common stock were converted.
The company withheld a total of 2,732 shares of common stock at $92.54 per share to satisfy tax withholding obligations, as disclosed in the footnotes. After these transactions, Phipps directly owned 67,760 shares of Zimmer Biomet common stock. These events reflect compensation-related vesting and tax withholding rather than open-market trading.
Zimmer Biomet Holdings Chairman, President and CEO Ivan Tornos exercised restricted stock units into 34,704 shares of common stock on March 6, 2026. The company withheld 19,195 shares at $92.54 per share to cover tax obligations, leaving him with 83,191 shares held directly.
Zimmer Biomet Holdings executive Wilfred Van Zuilen reported equity compensation activity involving restricted stock units and common shares. On February 25, 2026, he exercised 3,182 restricted stock units at $0.00 per unit, resulting in 3,182 shares of common stock acquired and increasing his direct common stock holdings to 26,637 shares before tax withholding.
As part of the same vesting event, 828 common shares valued at $99.51 per share were withheld by the company to cover tax obligations, leaving him with 25,809 directly held common shares. One-third of the restricted stock units vested on February 25, 2026, with the remaining units scheduled to vest in equal parts on February 25, 2027 and February 25, 2028.
Zimmer Biomet Holdings, Inc. executive Chad F. Phipps reported routine equity compensation activity. On February 25, 2026, 2,626 restricted stock units were converted into an equal number of common shares at no cash exercise price as part of a scheduled vesting.
To cover tax withholding on the RSU vesting, 1,057 common shares were withheld by the company at a price of 99.51 per share, as noted in the footnotes. After these transactions, Phipps directly owned 63,706 shares of common stock and 5,249 restricted stock units.
Zimmer Biomet Holdings executive Yi Sang reported an equity award vesting and conversion. On February 25, 2026, 2,785 restricted stock units were exercised and converted into 2,785 shares of common stock at a stated price of $0.00 per share.
Following these transactions, Yi Sang directly held 5,567 restricted stock units and 22,837 shares of common stock. According to the vesting schedule, one-third of the RSUs vested on February 25, 2026, with the remaining units vesting one-half on each of February 25, 2027 and February 25, 2028.
Zimmer Biomet Holdings senior vice president and chief human resources officer Lori Winkler reported equity transactions tied to restricted stock units. On February 25, 2026, 2,347 RSUs were exercised into 2,347 shares of common stock at $0.00 per share as part of an RSU vesting event. A footnote explains that one-third of the RSUs vested on that date, with the remainder vesting in equal parts on February 25, 2027 and February 25, 2028. To cover tax withholding on the vesting, 924 shares of common stock were withheld by the company at a reference price of $99.51 per share. After these transactions, Winkler directly held 9,418 shares of common stock and 4,693 RSUs.
Zimmer Biomet Holdings' Executive VP and CFO Suketu Upadhyay reported equity award activity involving restricted stock units and common shares. On February 25, 2026, he exercised 6,364 restricted stock units, converting them into 6,364 shares of common stock at a stated price of $0.0000 per share. Following this conversion, his direct holdings increased to 64,117 shares of common stock and 12,726 restricted stock units. On the same date, 2,832 common shares at $99.51 per share were withheld by the company to satisfy tax withholding obligations linked to the RSU vesting, rather than an open-market sale.
Zimmer Biomet Holdings Chairman, President and CEO Ivan Tornos reported equity award activity involving restricted stock units and common shares of ZBH. He exercised or converted 19,090 restricted stock units into 19,090 shares of common stock at a price of $0.0000 per share. To cover tax withholding on the RSU vesting, 10,557 common shares were withheld by the company at a price of $99.5100 per share, as described in the footnotes. Following these transactions on February 25, 2026, his directly held common stock position was 67,682 shares, and 38,179 restricted stock units remained outstanding, with one-third vesting on February 25, 2026 and the balance vesting in equal installments on February 25, 2027 and February 25, 2028.
Zimmer Biomet Holdings officer Paul A. Stellato reported equity compensation activity involving restricted stock units (RSUs) and common shares. On February 25, 2026, 820 RSUs were exercised and converted into 820 shares of common stock at a stated price of $0.0000 per share.
On the same date, 402 common shares were withheld at $99.5100 per share to cover tax withholding obligations related to the RSU vesting, as described in the footnotes. One-third of the RSUs vested on February 25, 2026, with the remaining RSUs scheduled to vest one-half on each of February 25, 2027 and February 25, 2028.
Following these transactions, Stellato directly held 1,638 RSUs and 4,527 shares of common stock. The disposition was for tax withholding rather than an open-market sale.
Noor Jehanzeb reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. reported that officer Noor Jehanzeb received a grant of 10,076 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of company common stock. The award vests annually over three years in one-third increments starting on February 20, 2027.